Skip to content

Clinical Study on Dose-effect Relationship of Maxing Ganshi Decoction on Treating Children with Bronchial pneumonia (Wind-heat Blocking the Lung)

Study on Dose-effect Relationship of Classical famous Prescription Based on Clinical Evaluation

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-TRC-13003093
Enrollment
Unknown
Registered
2013-03-07
Start date
2013-03-15
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Children with Bronchial pneumonia(Wind-heat Blocking the Lung)

Interventions

High-dose group:1. Maxing Shigan decoction, high dose of Shigao, 2. Routine treatment
Middle-dose group:1. Maxing Shigan decoction, middle dose of Shigao, 2. Routine treatment
Low-dose group:1. Maxing Shigan decoction, low dose of Shigao, 2. Routine treatment

Sponsors

First Teaching Hospital of Tianjin University of TCM
Lead Sponsor

Eligibility

Sex/Gender
All
Age
3 Years to 6 Years

Inclusion criteria

Inclusion criteria: 1. The disease has been diagnosed as pneumonia(wind-heat blocking the lung); 2. Pneumonia course is less than 48 hours; 3. The highest temperature is beyond 38.5 degree C during 24 hours before the beginning of the trial; 4. Aged 3 to 6 years old, body weight >=14kg; 5. WBC<=10*10^9 LN <70%; 6. CRP is normal; 7. Hospitalized patients; 8. Children's legal guardians have signed the ICF.

Exclusion criteria

Exclusion criteria: 1. the patient who has heart failure, respiratory failure, the toxic encephalopathy, exudative pleurisy and other complications; 2. The one who clearly merged with bacterial infection; 3. The one who has some serious primary diseases of heart, liver, kidney and hematopoietic system, the mentally illness; 4. According to the investigator's judgment, the one who has the possibility in reducing enrollment; 5. Children who cant cooperate or are participating in clinical trials of other drugs; 6. Allergic constitution; 7. According to the doctor's judgment, it's likely to cause the loss to follow.

Design outcomes

Primary

MeasureTime frame
Efficacy of Disease;Time of Fever Clearance;

Secondary

MeasureTime frame
Efficacy of TCM syndrome;Efficacy of individual symptoms (fever, cough, sputum);

Countries

China

Contacts

Public ContactRONG MA
marong1974@yahoo.com.cn+86 02227432012

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 7, 2026